Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Innovent Biologics' Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
GMP / GCP / GSPHKG: 1801

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Santen's Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China's NMPA for Myopia Progression
Market approval filingsOphthalmology

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

Anglikang PharmaceuticalCancer

Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody

CVDHKG: 9877

Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System

Show More